Manish R. Sharma
Experienced in Cutaneous T-Cell Lymphoma (CTCL)

Dr. Manish R. Sharma

Oncology
5800 Foremost Drive Southeast, Suite 100, 
Grand Rapids, MI 
On Staff At
Accepting New Patients
22 Years of Experience
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
5800 Foremost Drive Southeast, Suite 100, 
Grand Rapids, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Manish Sharma is an Oncologist in Grand Rapids, Michigan. Dr. Sharma has been practicing medicine for over 22 years and is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Ovarian Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, and Nephrectomy. Dr. Sharma is currently accepting new patients.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 28 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Cutaneous T-Cell Lymphoma (CTCL).

Graduate Institution
University Of Michigan Medical School, 2004
Residency
University of California, San Francisco, School of Medicine
Specialties
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
Hospital Affiliations
Corewell Health Grand Rapids Hospitals
Corewell Health Zeeland Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

The Cancer & Hematology Centers - Foremost Drive Ste 100
5800 Foremost Drive Southeast, Suite 100, Grand Rapids, MI 49546

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drugs: MGC018, MGA012
Study Phase: Phase 1/Phase 2
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma
Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drug: TH1902
Study Phase: Phase 1
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: March 06, 2025
Intervention Type: Biological
Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4
Study Phase: Phase 1
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: LY3475070, Pembrolizumab
Study Phase: Phase 1
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: PDR001, INC280
Study Phase: Phase 1/Phase 2
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 Via Intravenous Infusion in Patients With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 24, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
View 27 Less Clinical Trials

48 Total Publications

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.
Journal: Journal of hematology & oncology
Published: January 06, 2025
Similar Doctors
Advanced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Muhammad W. Usman
Hematology Oncology | Oncology
Advanced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Muhammad W. Usman
Hematology Oncology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (66.9 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhammad Usman is a Hematologist Oncology specialist and an Oncologist in Kalamazoo, Michigan. Dr. Usman is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Hemophilia A, Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, and Hemophilic Arthropathy. Dr. Usman is currently accepting new patients.

Erin M. Pettijohn
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Erin M. Pettijohn
Oncology | Hematology | Hematology Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Erin M. Pettijohn
Oncology | Hematology | Hematology Oncology

The Cancer & Hematology Centers

710 Kenmoor Avenue Southeast, Suite 200, 
Grand Rapids, MI 
 (37.1 miles away)
616-389-1800
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Erin Pettijohn is a Hematologist and a Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Pettijohn has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Large-Cell Immunoblastic Lymphoma, B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Pettijohn is currently accepting new patients.

Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Carol R. Rapson
Hematology Oncology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Carol R. Rapson
Hematology Oncology | Oncology

Cancer And Hematology Centers Of Western Mi, P.C.

5800 Foremost Dr Se, Suite 100, 
Grand Rapids, MI 
 (37.1 miles away)
616-954-5554
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carol Rapson is a Hematologist Oncology specialist and an Oncologist in Grand Rapids, Michigan. Dr. Rapson is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Rapson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sharma's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile